Pure-play Psychedelic Compound-Based Drug Discovery Stocks Plummet 14%: Why

sábado, 8 de noviembre de 2025, 5:12 pm ET1 min de lectura
CMPS--
GHRS--
MNMD--

The "Big 4" psychedelic compound-based drug discovery stocks fell 14% last week. The stocks are focused on developing therapies for mental health disorders and addiction/substance abuse. The companies included in the portfolio are GH Research PLC, COMPASS Pathways, Usona Institute, and Mind Medicine (MindMed). The stocks fell due to technical breakouts, bullish analyst sentiment, and momentum-driven inflows despite conflicting valuation models.

Pure-play Psychedelic Compound-Based Drug Discovery Stocks Plummet 14%: Why

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios